Here's the link:

http://www.medgadget.com/2016/01/epigenetics-market-all-set-to-reach-16-31-billion-by-2022-grand-view-research-inc.html

Of particular note is this part:

• Non oncology segment is anticipated to register the fastest growth of over 20.0% during the forecast period. The segment is dominated by metabolic diseases owing to, the growing base of population suffering from diabetes and organ failure and increasing prevalence of sedentary lifestyle.